Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Iva Staniczková Zambo"'
Autor:
Michal Mahdal, Lukáš Pazourek, Vasileios Apostolopoulos, Dagmar Adámková Krákorová, Iva Staniczková Zambo, Tomáš Tomáš
Publikováno v:
Current Oncology, Vol 29, Iss 5, Pp 3519-3530 (2022)
Background: The purpose of this study was to evaluate the implant survival, functional score and complications of intercalary endoprostheses implanted for metastatic involvement of the femoral and humeral diaphysis. Methods: The selected group covere
Externí odkaz:
https://doaj.org/article/b0f452dea6804d71a803eace9ce6dafd
Autor:
Michal Mahdal, Tomáš Tomáš, Vasileios Apostolopoulos, Dagmar Adámková, Peter Múdry, Iva Staniczková Zambo, Lukáš Pazourek
Publikováno v:
Cancers, Vol 15, Iss 18, p 4664 (2023)
Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates
Externí odkaz:
https://doaj.org/article/51c15e8a354540efae09f25ee316b9bf
Autor:
Peter Múdry, Michal Kýr, Ondřej Rohleder, Michal Mahdal, Iva Staniczková Zambo, Marta Ježová, Tomáš Tomáš, Jaroslav Štěrba
Publikováno v:
Journal of Bone Oncology, Vol 28, Iss , Pp 100362- (2021)
Purpose: Conventional osteosarcoma is an orphan disease. Current treatment approaches include combining a three drug chemotherapy schedule and surgery. The 3- and 5-year event-free survival (EFS) in localized disease is roughly 65 and 60%, respective
Externí odkaz:
https://doaj.org/article/d2c6f7ddce29434c93d6a72a9563cdf9
Autor:
Iva Staniczková Zambo, Jiri Urban, Tomáš Tomáš, Michal Mahdal, Jakub Neradil, Renata Veselská, Peter Macsek, Peter Múdry, Silvia Paukovcekova, Lukáš Pazourek
Publikováno v:
Cancers, Vol 13, Iss 3543, p 3543 (2021)
Cancers
Volume 13
Issue 14
Cancers
Volume 13
Issue 14
Simple Summary The purpose of this study was to analyze differential cell signaling in response to denosumab treatment to identify and subsequently inhibit molecular targets in the neoplastic stromal cell population, which poses a risk for tumor recu
Autor:
Iva Staniczková Zambo, Michal Mahdal, Jaroslav Štěrba, Michal Kýr, Peter Múdry, Tomáš Tomáš, Ondřej Rohleder, Marta Ježová
Publikováno v:
Journal of Bone Oncology
Journal of Bone Oncology, Vol 28, Iss, Pp 100362-(2021)
Journal of Bone Oncology, Vol 28, Iss, Pp 100362-(2021)
Highlights • A report on the best treatment results on an osteosarcoma cohort. • There has been a lack of improvement in osteosarcoma treatment for the last four decades. • Mifamurtide is the only new drug against osteosarcoma licensed by the E
Autor:
Michal Mahdal, Jakub Neradil, Peter Mudry, Silvia Paukovcekova, Iva Staniczkova Zambo, Jiri Urban, Peter Macsek, Lukas Pazourek, Tomas Tomas, Renata Veselska
Publikováno v:
Cancers, Vol 13, Iss 14, p 3543 (2021)
Giant-cell tumor of bone (GCTB) is an intermediate type of primary bone tumor characterized by locally aggressive growth with metastatic potential. The aim of this study was to identify new druggable targets among the cell signaling molecules involve
Externí odkaz:
https://doaj.org/article/0359ddf0f0ab42c5a01569643702929b
Autor:
Jan Skoda, Jakub Neradil, Iva Staniczkova Zambo, Alena Nunukova, Peter Macsek, Karolina Borankova, Viera Dobrotkova, Pavel Nemec, Jaroslav Sterba, Renata Veselska
Publikováno v:
Cancers, Vol 12, Iss 1, p 196 (2020)
Serial xenotransplantation of sorted cancer cells in immunodeficient mice remains the most complex test of cancer stem cell (CSC) phenotype. However, we have demonstrated in various sarcomas that putative CSC surface markers fail to identify CSCs, th
Externí odkaz:
https://doaj.org/article/ce6a6716fcb24b558d97a6cf0d6ad4b0